Clinical Trial Update: Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating sequential chemotherapy with befotertinib in non-small cell lung cancer patients who have developed resistance to third…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Befotertinib

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: NSCLC, Adjuvant Drug Therapy | Phase 2 | Status: RECRUITING